### ANUH PHARMA LTD.

## CIN: L24230MH1960PLC011586

Regd. Office: 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018 Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2020

Sr. No.   Particulars						(Rs. in Lakhs)
(1) (2) (3) (4) (5) (6)  1. Revenue from operations 12,242.77 7,205.25 8,489.43 30,69  11. Other income 309.64 110.63 125.64 4.  111. Total Revenue (1+11) 12,734.41 7,315.88 8,615.07 31,1  IV. Expenses:  Cost of materials consumed 6,676.20 6,600.16 5,889.60 23,99  Purchases of Stock-in-Trade 173.75 34.00 89.84 44  Changes in inventories of finished goods, work-in- progress and Stock-in-Trade 2,739.00 (1,539.07) 664.08 (1,3)  Finance costs 344.20 370.52 312.38 1,3  Finance costs 44.80 54.34 7,93 7.  Depreciation and amortization expense 344.20 370.52 312.38 1,3  Finance costs 44.80 54.34 7,93 7.  Other expenses 1,139.08 1,550.08 761.68 4,00  Total expenses (IV) 10,504.25 7,477.53 7,817.49 29,24  V. [III -1V]  V. [III -1V]  Exceptional items 1,191.00 (161.65) 797.58 1,91  VIII Profit /(Loss) before exceptional and items and tax (2) 230.16 (161.65) 797.58 1,91  VIII Tax expense: 49.00 (196.00) 214.00 37  (2) Deferred tax 59.00 (196.00) 214.00 37  (3) MAT Credit Entitlement 59.00 (196.00) 214.00 37  IX Profit/(Loss) after Tax (VII-VIII) 1,672.10 (92.00) 587.37 1,41  X Other Comprehensive Income (net of Tax) (10.59 3.15 (7.61) 10.59  (i) Items that will not be reclassified to profit or loss 10.59 3.15 (7.61) 10.59  Total Other Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.682.69 (88.85) 579.76 1,45  Comprehensive Income (net of Tax) 1.	1 1	Particulars -	ended	ended	ended	12 months ended 31/03/2020
I.   Revenue from operations   12,424.77   7,205.25   8,489.43   30,61     II.   Other income   309.64   110.63   125.64   44     III.   Total Revenue (I + II)   12,734.41   7,315.88   8,615.07   31,1     IV.   Expenses:			Unaudited	Audited	Unaudited	Audited
II.   Other income	(1)	(2)	(3)	(4)	(5)	(6)
III.   Total Revenue (I+1I)   12,734.41   7,315.88   8,615.07   31,1     IV.   Expenses:	I. R	Revenue from operations	12,424.77	7,205.25	8,489.43	30,695.96
IV.   Expenses:	II. C	Other income	309.64	110.63	125.64	421.23
Cost of materials consumed   6,676.20   6,600.16   5,889.60   23,90	III.	Total Revenue (I + II)	12,734.41	7,315.88	8,615.07	31,117.19
Purchases of Stock-in-Trade	IV. E	Expenses:				
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade   1,753.09   (1,539.07)   664.08   (1,3)	C	Cost of materials consumed	6,676.20	6,600.16	5,889.60	23,965.58
progress and Stock-in-Trade   1,733.09   (1,539.07)   664.08   (1,3)			173.75	34.06	89.84	401.45
Finance costs		• , ,	1,753.09	(1,539.07)	664.08	(1,350.76)
Depreciation and amortization expense   373.04   406.64   91.98   770	Е	Employee benefits expense	344.29	370.52	312.38	1,336.23
Other expenses	F	inance costs	44.80	54.54	7.93	79.22
Total expenses (IV)	D	Depreciation and amortization expense	373.04	406.64	91.98	703.26
V.   Profit / (Loss) before exceptional and items and tax (III - IV)   2,230.16 (161.65)   797.58   1,99     VII.   Exceptional items       VII.   Profit / (Loss) before tax (V - VI)   2,230.16 (161.65)   797.58   1,99     VIII.   Tax expense:       (1) Current tax   549.00 (196.00)   214.00   33     (2) Deferred tax   9.06   142.02 (3.79)   11     (3) MAT Credit Entitlement   (15.67)   (1.67)     (3) MAT Credit Entitlement   558.06 (69.65)   210.21   44     IX.   Profit / (Loss) after Tax (VII-VIII)   1,672.10 (92.00)   587.37   1,41     X.   Other Comprehensive Income (net of Tax)   (i) Items that will not be reclassified to profit or loss     -     (ii) Items that will be reclassified to profit or loss     -     Total Other Comprehensive Income (net of Tax)   10.59   3.15 (7.61)     Total Other Comprehensive Income (net of Tax)   10.59   3.15 (7.61)     Total Other Profit / (Loss) and Other   1,682.69 (88.85)   579.76   1,47     Comprehensive Income for the period (IX +	0	Other expenses	1,139.08	1,550.68	761.68	4,066.65
VI. Exceptional items  VI. Profit / (Loss) before tax (V - VI)  VI. Exceptional items			10,504.25	7,477.53	7,817.49	29,201.63
VII.       Profit / (Loss) before tax (V - VI)       2,230.16       (161.65)       797.58       1,91         VIII       Tax expense:       (1) Current tax       549.00       (196.00)       214.00       37         (2) Deferred tax       9.06       142.02       (3.79)       12         (3) MAT Credit Entitlement       - (15.67)       -	V. (I	III - IV)	2,230.16	(161.65)	797.58	1,915.56
VIII         Tax expense:         (1) Current tax         549.00         (196.00)         214.00         33           (2) Deferred tax         9.06         142.02         (3.79)         13           (3) MAT Credit Entitlement         -         (15.67)         -         (6           IX         Profit/(Loss) after Tax (VII-VIII)         1,672.10         (92.00)         587.37         1,43           X         Other Comprehensive Income (net of Tax)         (10.59)         3.15         (7.61)           (ii) Items that will not be reclassified to profit or loss         -         -         -           (ii) Items that will be reclassified to profit or loss         -         -         -           (ii) Items that will not be reclassified to profit or loss         -         -         -           (ii) Items that will not be reclassified to profit or loss         -         -         -           (iii) Items that will be reclassified to profit or loss         -         -         -         -           (ii) Items that will not be reclassified to profit or loss         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -	VI. E	exceptional items	-	_	-	
(1) Current tax 549.00 (196.00) 214.00 33 (2) Deferred tax 9.06 142.02 (3.79) 13 (3) MAT Credit Entitlement - (15.67) - (15.67			2,230.16	(161.65)	797.58	1,915.56
(2) Deferred tax						
(3) MAT Credit Entitlement - (15.67)	(1	1) Current tax	549.00	(196.00)	214.00	370.00
S58.06   (69.65)   210.21   44	(2	2) Deferred tax	9.06	142.02	(3.79)	130.70
IX Profit/(Loss) after Tax (VII-VIII)  X Other Comprehensive Income (net of Tax)  (i) Items that will not be reclassified to profit or loss  (ii) Items that will be reclassified to profit or loss  Total Other Comprehensive Income (net of Tax)  Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)  Paid up Equity Share Capital (Face value Rs. 5/each)  Other Equity (excluding revaluation reserves)  XII Earnings per equity share (Non annualised) (In Rs.)  (1) Basic  (6.67 (0.37) 2.34	(3	3) MAT Credit Entitlement	-	(15.67)	-	(15.67)
X Other Comprehensive Income (net of Tax)  (i) Items that will not be reclassified to profit or loss  (ii) Items that will be reclassified to profit or loss  Total Other Comprehensive Income (net of Tax)  Total Comprehensive Income for the period (IX + XI X) (Comprehensive Income for the period)  Paid up Equity Share Capital (Face value Rs. 5/- each)  Other Equity (excluding revaluation reserves)  XII Earnings per equity share (Non annualised) (In Rs.)  (1) Basic  (2.61)  (7.61)  (7.61)  (88.85)  (7.61)  (88.85)  (7.61)  (88.85)  (7.61)		MANUFACTURE CONTRACTOR	558.06	(69.65)	210.21	485.03
(i) Items that will not be reclassified to profit or loss  (ii) Items that will be reclassified to profit or loss  Total Other Comprehensive Income (net of Tax)  Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)  Paid up Equity Share Capital (Face value Rs. 5/- each)  Other Equity (excluding revaluation reserves)  (1) Basic  (7.61)  (7.			1,672.10	(92.00)	587.37	1,430.53
loss						
Total Other Comprehensive Income (net of Tax)   10.59   3.15   (7.61)		1	10.59	3.15	(7.61)	(9.22)
Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)  Paid up Equity Share Capital (Face value Rs. 5/each)  Other Equity (excluding revaluation reserves)  XII Earnings per equity share (Non annualised) (In Rs.)  (1) Basic  (1) Basic  (88.85)  579.76  1,42  1,252.80  1,252.80  1,252.80  1,252.80  1,252.80  1,252.80  2.34	(	(ii) Items that will be reclassified to profit or loss	-	-	-	-
XI   X) (Comprising Profit / (Loss) and Other   1,682.69   (88.85)   579.76   1,42	Te	otal Other Comprehensive Income (net of Tax)	10.59	3.15	(7.61)	(9.22)
Paid up Equity Share Capital (Face value Rs. 5/- each)  Other Equity (excluding revaluation reserves)  XII Earnings per equity share (Non annualised) (In Rs.)  (1) Basic  6.67  (0.37)  1,252.80  1,252.80  1,252.80  1,252.80  1,252.80  1,252.80  2.34	XI X	) (Comprising Profit / (Loss) and Other	1,682.69	(88.85)	579.76	1,421.31
Other Equity (excluding revaluation reserves)  XII Earnings per equity share (Non annualised) (In Rs.)  (1) Basic 6.67 (0.37) 2.34	Pa	aid up Equity Share Capital (Face value Rs. 5/-	1,252.80	1,252.80	1,252.80	1,252.80
(1) Basic 6.67 (0.37) 2.34					***************************************	14,967.94
	XII Ea	arnings per equity share (Non annualised) (In Rs.)				MINUTE.
(2) Diluted 6.67 (0.37) 2.34	(1)	) Basic	6.67	(0.37)	2,34	5.71
	(2)	) Diluted	6.67	(0.37)	2.34	5.71



#### Notes:-

1. The results of the quarter ended 30th June,2020 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 07th August, 2020. The statutory auditors of the company carried out a "Limited Review" of the financial results for quarter ended 30th June, 2020.

2. Other Financial indicators

(Rs. in Lakhs)

(MU

				(**************************************
	3 months	3 months	3 months	12 months
Particulars	ended	ended	ended	ended
	30/06/2020	31/03/2020	30/06/2019	31/03/2020
EBITDA	2,648.00	299.53	897.49	2,698.04
% of EBITDA Margin	21.31	4.16	10.57	8.79
EBITDA (Adjusted to Forex (gain) / loss and Mark to Market (gain) / loss on Investment in Mutual funds)	2,736.53	840.32	840.07	3,433.09
% of Adjusted EBITDA Margin	22.02	11.66	9.90	11.18

- 3. The figures for the quarter ended 31st March, 2020 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.
- 4. The Board of Directors has recommended issue of bonus shares in the ratio of 1 equity share of Rs.5/- each for every 1 equity share of Rs.5/- each (1:1), which is subject to the approval of members of the Company by way of ordinary resolution through upcoming AGM and e-voting.
- 5. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.
- 6. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Limited

Bipin N. Shah Managing Director

(DIN: 00083244)

Place : Mumbai

Dated: 07th August, 2020

# JAYANTILAL THAKKAR & CO. CHARTERED ACCOUNTANTS

111 (A), MAHATMA GANDHI ROAD, FORT, MUMBAI - 400 023. TELEPHONES :2265 8800

2265 8900

FAX: (91 - 22) 2265 8989 E-MAIL: jtee@vsnl.net

jtco23@jtco.co.in

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

# Review Report to The Board of Directors Anuh Pharma Limited

- We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter ended June 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



PLACE: Mumbai

DATE: 7th August,2020

For JAYANTILAL THAKKAR & CO. CHARTERED ACCOUNTANTS (FIRM REG. NO. 104133W)

VIRAL A. MERCHANT

PARTNER MEMBERSHIP NO. 116279

UDIN: 20116279AAAAAY 7205